

1 **Five years functional connectivity reorganization without clinical or cognitive decline in MS**

2

3 Einar August Høgestøl^{a, b}, Samuele Ghezzi^{*, c, d}, Gro Owren Nygaard^a, Thomas Espeseth^{e, f}, Piotr Sowa^g,
4 Mona K. Beyer^{b, g}, Hanne Flinstad Harbo^{a, b}, Lars T. Westlye^{c, e, h}, Hanneke E. Hulst^{d, i}, Dag Alnæs^c

5 ^a Oslo University Hospital, Department of Neurology, Oslo, Norway

6 ^b University of Oslo, Institute of Clinical Medicine, Oslo, Norway

7 ^c NORMENT, Division of Mental Health and Addiction, Oslo, Norway

8 ^d Vrije Universiteit Amsterdam, Department of Neuroscience, Amsterdam, The Netherlands

9 ^e University of Oslo, Department of Psychology, Oslo, Norway

10 ^f Bjørknes College, Oslo, Norway

11 ^g Oslo University Hospital, Division of Radiology and Nuclear Medicine, Oslo, Norway

12 ^h University of Oslo, KG Jebsen Centre for Neurodevelopmental Disorders, Oslo, Norway

13 ⁱ Amsterdam UMC, Amsterdam Neuroscience, Department of Anatomy and Neurosciences, MS Center
14 Amsterdam, Amsterdam, The Netherlands

15

16 * Einar August Høgestøl and Samuele Ghezzi contributed equally to this work as first authors.

17

18 **Keywords:** multiple sclerosis, functional neuroimaging, fMRI, cohort studies, all
19 neuropsychological/behaviour

20 **Corresponding author:**

21 Einar August Høgestøl

22 Department of Neurology, Neuroscience Research Unit, Multiple Sclerosis Research Group University of

23 Oslo & Oslo University Hospital

24 Domus Medica 4, room L-268, Gaustadalleén 34

25 0372 Oslo, Norway

26 E-mail: einar.august@gmail.com

27 Mobile: +47 41 10 89 81

28

29 Characters in title: 93 (Max 96)

30 Abstract: 249 (Max 250)

31 Introduction: 250 (Max 250)

32 Main text: 4269 (Max 4500)

33 References: 44 (Max 50)

34 Items: 7 (Max 7)

35 **ABSTRACT**

36 **Objective:** 1) To assess fMRI-based functional connectivity (FC) anomalies in early multiple sclerosis
37 (MS), 2) To determine the relation between FC changes and structural brain damage due to disease
38 progression 3) To study the association between FC changes and cognitive and physical disability.

39 **Methods:** Structural MRI and resting-state fMRI were acquired from 76 early relapsing-remitting MS
40 patients at baseline (average disease duration 71.7 months \pm 63) and after five years. Ninety-four
41 healthy controls (HCs) matched for age and sex were included at baseline. Independent component
42 analysis (ICA) and network modelling were used to measure FC. FC variation was related to
43 expanded disability status scale and neuropsychological outcomes. Brain and lesion volumes were
44 quantified using standard methods. We used the 25 independent components obtained from ICA to
45 estimate the longitudinal stability of the brain connectome as a proxy for functional reorganization
46 over time.

47 **Results:** The MS subjects were clinically and cognitively stable. Compared to HCs, FC abnormalities
48 were detected within networks and in single connections in patients with early MS at baseline. Over
49 time, FC was relatively invariable, but changes in FC were associated with progression of brain
50 atrophy ($p = 0.39$, $p = .06$). No significant relationship with clinical and cognitive measures or lesion
51 load was detected.

52 **Conclusion:** Patients with MS showed evidence of altered FC in the early stages of the disease. Over
53 time, changes in FC seem to be related to a progression of brain atrophy, which are known to
54 precede changes in clinical and cognitive functioning.

55 INTRODUCTION

56 Multiple sclerosis (MS) is a disease characterized radiologically by the accumulation of lesions in grey
57 and white matter over time throughout the CNS^{1, 2}. Brain white matter constitutes the structural
58 connectivity backbone supporting large-scale brain functional network connectivity^{3, 4}. Accumulating
59 evidence has demonstrated abnormal patterns of brain functional connectivity (FC) in MS patients as
60 compared to healthy controls (HCs)⁵⁻¹². Extensive evidence shows that FC abnormalities are
61 associated with clinical disability in MS^{5, 6, 8-10, 12}, with a complex pattern of the directionality of FC
62 effects¹³. A longitudinal approach that accounts for all alterations in FC following structural damage
63 in MS is warranted to better understand the complex interplay between disease progression and FC
64 reorganization¹³.

65 We investigated a prospectively collected MS cohort with comprehensive imaging and
66 clinical data at two time points over five years. First, we explored the baseline resting-state (rs) fMRI
67 MS-data and compared this to a group of age-matched HCs from the same scanner. Then, we used
68 rs-fMRI data to compute the longitudinal stability of each patients' brain functional connectome¹⁴,
69 reducing the complex dynamics of the functional connectome into a single, individual-level global
70 marker of longitudinal network reorganization. The resulting rs-fMRI global measure of connectome
71 stability was compared to brain atrophy, lesion load and clinical and cognitive outcomes. Our
72 hypotheses were 1) MS affects FC in early stages of disease, 2) disease progression is associated with
73 FC reorganization over a five-year interval and 3) an individual-level global measure of connectome
74 stability is associated with clinical trajectories in MS.

75 METHODS

76 Participants

77 We included 76 MS patients from a prospective longitudinal study at Oslo University Hospital¹⁵⁻¹⁷. All
78 patients were diagnosed between January 2009 and October 2012 with relapsing-remitting MS
79 (RRMS) according to the revised McDonald Criteria¹⁸. One patient originally categorized as RRMS

80 was later re-evaluated to be primary-progressive (PP) MS, although with relapses and MRI activity.
81 The patient was excluded from image analysis due to missing rs-fMRI data. Early MS was defined as
82 within the first 10 years of MS symptoms onset. Six participants were not examined with the rs-fMRI
83 sequence at baseline, resulting in 70 patients eligible for the image analyses. All participants were
84 invited for follow-up, five years after the first time point. At follow-up, 62 patients were assessed,
85 with two patients missing the rs-fMRI sequence. Inclusion criteria included age between 18 and 50
86 years, < 3 years since diagnosis of RRMS at baseline, ≥ 6 weeks since the last relapse or corticoid
87 treatment, fluency in Norwegian language, right handedness, no prior neurological or psychiatric
88 disease, no head injury and no substance abuse. We excluded pregnant or breastfeeding patients
89 and a patient with a previous adverse reaction to gadolinium injection.

90 Cross-sectional data from HC (n=94, age- and sex-matched with respect to the patient
91 sample) were sampled from the Norwegian Cognitive NeuroGenetics (NCNG) cohort, recruited
92 through newspaper advertisements in the Oslo area¹⁹. Inclusion criteria were age between 20 and
93 80 years, no previous diseases affecting the CNS and no previous or current substance abuse.

94 **Neurological assessment**

95 All MS patients completed a comprehensive neurological examination at baseline and follow-up,
96 including assessment of the expanded disability status scale (EDSS) within the same week as the MRI
97 scan. Physical ability of MS patients was assessed using the Timed 25-Foot Walk (T25-FW) and the 9-
98 hole peg test. No evidence of disease activity (NEDA) -3 was defined as the absence of clinical
99 relapses, new or enlarging MRI lesions and clinical progression as measured by EDSS. First line
100 treatment included interferons, glatiramer acetate, teriflunomide and dimethyl fumarate, while
101 second line treatment included fingolimod, natalizumab and alemtuzumab.

102 Furthermore, all subjects completed a fatigue self-report questionnaire (FSS)²⁰ and
103 underwent cognitive evaluation. FSS mean scores of ≥ 5 were defined as clinically significant
104 fatigue²¹. The cognitive evaluation included tests for processing speed, executive functioning,

105 visuospatial and verbal memory (see Supplemental). In order to obtain a measure of average
106 cognition we first calculated Z-scores for each of the tests administered. Then, we averaged Z-scores
107 within the four cognitive domains previously described, and eventually we averaged the scores
108 across domains, obtaining a measure of overall cognition for each of the MS patients at both time
109 points. Similarly, we averaged the Z-scores for T25-FW and 9-hole peg test to obtain a measure of
110 physical ability.

111 Cross-sectional California Verbal Learning Test-II (CVLT-II) and colour-word interference test
112 (CWIT) data from the NCNG HC sample and summary statistics for the remaining tests obtained from
113 an Amsterdam HC sample²² were used for comparison with the patient group. We considered an
114 annual decline of 0.25 SD in average cognition and physical performance as significant²².

115 **MRI acquisition and structural MRI pre- and post-processing**

116 All MS and HC subjects were scanned using the same 1.5 T scanner (Avanto, Siemens Medical
117 Solutions; Erlangen, Germany) equipped with a 12-channel head coil. For rs-fMRI we used a T2*
118 weighted echo-planar imaging (EPI) sequence (repetition time (TR)=3000 milliseconds (ms), echo
119 time (TE)=70 ms, flip angle (FA)=90°, voxel size=3.44x3.44x4 mm, field-of-view (FOV)=220,
120 descending acquisition, GeneRalized Auto calibrating Partial Acquisition (GRAPPA) acceleration
121 factor=2), 28 transversally oriented slices, no gap, with a scan time of 7 minutes and 30 seconds. The
122 rs-fMRI at baseline included 150 volumes, while the follow-up rs-fMRI scan yielded 100 volumes. The
123 rs-fMRI scan for the HCs constituted of 300 volumes. For fMRI pre-processing and analyses we
124 restricted the rs-fMRI data to the first 100 volumes for all participants. Three dummy volumes were
125 collected to avoid T1 saturation effects. Structural MRI data were collected using a 3D T1-weighted
126 Magnetization Prepared Rapid Gradient Echo (MP-RAGE) sequence (TR=2400 ms, TE=3.61 ms, time
127 to inversion=1000 ms, FA=8°, matrix 192x192, field of view=240, scan time 7 minutes and 42
128 seconds, sagittal slices=160, voxel size =1.20x1.25x1.25 mm). FLAIR sequence parameters were
129 TR=6000 ms, TE=3.33 ms, time to inversion=2200 ms, FOV=260, FA=variable T2, matrix 256 × 204.

130 Each scan lasted 7 minutes and 2 seconds, sagittal slices=176 slices, slice thickness=1 mm, voxel size
131 1.0x1.0x1.0.

132

133 We performed cortical reconstruction by using the T1-weighted scans and volumetric
134 segmentation with FreeSurfer 5.3 (<http://surfer.nmr.mgh.harvard.edu/>)²³. To extract reliable volume
135 and thickness estimates, images included in the longitudinal MS MRI dataset were processed with
136 the longitudinal stream in FreeSurfer²⁴. To further validate the brain volume measure, we studied its
137 association with lesion-filled masks at baseline (see table e-1 in Supplemental data). Lesion volume
138 was based on LesionQuant output^{25, 26}. To validate the lesion output by LesionQuant we additionally
139 assessed its association with lesion masks previously acquired using Cascade and validated by an
140 experienced neuroradiologist at baseline²⁷ (see table e-1 in Supplemental data).

141 **fMRI pre-processing**

142 fMRI was performed using FMRI Expert Analysis Tool (FEAT) Version 6.00, from FMRIB's Software
143 Library (<https://fsl.fmrib.ox.ac.uk/>)²⁸. Head motion was corrected using MCFLIRT²⁹ before linear
144 trends and low-frequency drifts were removed (high-pass filter of 0.01 Hertz). fMRI images were
145 carefully examined by trained research personnel for image artefacts, such as head motion and
146 missing coverage of the scan window. In total, fMRI scans from ten patients and 13 HCs at baseline
147 and eight patients at follow-up were discarded due to incomplete coverage of the visual and parietal
148 cortex. Scans in which the mean relative motion parameter (defined as the average of the
149 translational motion for each scan relative to the previous scan) exceeded 2.5 SD from the average
150 of all runs (across scans) were discarded (none in our MS sample). Brain extraction tool³⁰ was used to
151 remove non-brain tissue. Spatial smoothing was performed using a Gaussian kernel filter with a full
152 width at half maximum (FWHM) of 6 mm³¹. FMRIB's Nonlinear Image Registration tool (FNIRT) was
153 used to register the participants fMRI volumes to Montreal Neurological Institute (MNI) 152
154 standard using the T1-weighted scan as an intermediate, which had the non-brain tissue removed


155 using procedures for automated volumetric segmentation in Freesurfer 5.3

156 (<http://surfer.nmr.mgh.harvard.edu/>)²³.

157 Single-session independent component analysis (ICA) was performed for all runs using
158 Multivariate Exploratory Linear Optimized Decomposition into Independent Components
159 (MELODIC)³². We used FIX³³ for automatic classification of the single-session ICA into signal and noise
160 components, in order to regress noise components from fMRI data. Data cleaning also included
161 correction based on the estimated motion parameters for each run, using linear regression. These
162 ICA-based procedures for denoising of fMRI-data efficiently reduce motion induced variability,
163 outperforming methods based on regression of motion parameters, scrubbing or de-spiking³⁴.

164 **ICA and functional connectivity matrices**

165 The cleaned and MNI-conformed rs-fMRI datasets were submitted to temporal concatenation group
166 independent component analysis (gICA) using MELODIC³² with a model order of 40. These group
167 level spatial components were then used as spatial repressors against the original rs-fMRI datasets
168 to estimate subject-specific components and associated time series (dual regression)³⁵. After
169 removing 15 ICs that originated in non-CNS areas and therefore were classified as noise components
170 by a careful evaluation, we extracted a total of 25 ICs for further analysis. The times series of the
171 noise-ICs were regressed out of the time series of the kept ICs. We then calculated connectivity
172 matrices using full as well as regularized partial correlations with automatic estimation of
173 regularization parameters at the individual level^{36, 37}. Based on the Euclidean distances of the full
174 temporal correlations, the ICs grouped into four clusters largely representing (1) and (2) default
175 mode network (DMN) and frontoparietal areas, (3) auditory network and (4) sensory/motor areas
176 (figure 1). For detailed information regarding the specific ICs or the anatomical constitution of the
177 networks, please refer to [table e-2 in Supplemental Data](#). Finally, since partial correlations are
178 assumed to represent direct connections between nodes, these were used in further analyses of
179 case-control differences and connectome stability.



180

181 **Figure 1** Hierarchical clustering of brain nodes. (A) Dendrogram showing the clustering of the nodes,
182 based on the full correlations across conditions and participants. The colours of the dendrograms
183 represent the four ICA clusters (1), (2), (3) and (4), from left to right. (B) The 25 ICs from group ICA
184 used in the analyses. (C) The full correlation matrix across conditions and participants is shown
185 below the diagonal. Regularized partial correlation across conditions are presented above the
186 diagonal. Warm colours indicate positive correlations, cold colours negative correlations.

187

188 **Connectome stability**

189 We computed the stability of the brain functional connectome for each MS patient as a proxy for FC
190 reorganization. We vectorized each participant's whole-brain connectivity matrix, creating a vector
191 of size 1×300 (25 ICs and 300 unique links between them). Then, we calculated the within subjects
192 Spearman correlation coefficient between fMRI at baseline and follow-up, in this way obtaining a
193 measure of whole-brain connectome stability¹⁴. Similarly, we computed the within-network
194 connectome stability for each of the four clusters previously identified. Alterations in the rank of
195 edges across the connectome between baseline and follow-up, independent of their direction, will

196 be reflected in the connectome stability, providing an individual global and network-specific
197 measure of FC reorganization for the MS patients. To further validate the implementation of the
198 stability of the brain functional connectome as a measure that accounts for all changes in FC over
199 time, we correlated connectome stability with the sum of the squared differences in FC between
200 baseline and FU for all edges in each of the MS patients.

201 **Statistical analysis**

202 For statistical analyses, we used R³⁸ and MATLAB version 2014a (The MathWorks Inc., Natick, MA,
203 2018). The changes in performance for all cognitive and clinical tests between baseline and follow-
204 up were measured by paired sample t-tests.

205 We used separate multivariate linear models to test for differences in whole brain FC, within
206 network FC, and FC at the level of single edges between HCs and MS patients at baseline. We
207 performed paired sample t-tests to assess changes in FC over time in the MS cohort.

208 To investigate whether disease progression was associated with functional reorganization,
209 we used separate multivariate linear models to compare whole brain, and within network,
210 connectome stability between patients that showed evidence of disease activity (EDA) and patients
211 with NEDA. To further test the hypothesis that structural damage due to disease progression is
212 associated with a reduction in the stability of the functional connectome we correlated whole brain
213 functional connectome stability of EDA patients with measures of brain volume loss and
214 accumulation of lesion load over five years. For lesion volumes we used log transformation, plus a
215 constant $k = 2$, to account for the lack of normal distribution in the resulting volumes.

216 Finally, we used multivariate linear models to assess the relationship between connectome
217 stability with cognition and physical ability at follow-up, and on the change in these tests between
218 baseline and follow-up.

219 We adjusted for sex, age, mean relative motion and signal to noise ratio in all linear models.
220 Significance was defined as $p < .05$ in all the performed tests. In the first part of the study, when we

221 compared FC between HCs and MS patients and later investigated changes in FC over time in the MS
222 cohort, we corrected p value for multiple testing by false discovery rate. Due to the limited sample
223 size of the subgroups, we used permutation testing to correct p value for multiple testing in the
224 comparisons of connectome stability between EDA and NEDA patients. Specifically, we obtained an
225 empirical null-distribution of estimates for the group difference across 1000 permutations randomly
226 permuting the group-label. The family wise error was controlled by collecting the maximum test
227 statistic across the whole brain and within-network tests for each permutation³⁹. The resulting p
228 value was calculated by dividing the number of permuted beta-values equal or larger than the point
229 estimate by the total number of permutations.

230 **Standard protocols approval, registrations, and patient consents**

231 The project was approved by the regional ethical committee of South Eastern Norway (REC ID:
232 2011/1846, 2016/102 and 2009/2070), and all participants received oral and written information
233 and gave their written informed consent.

234 **Data availability**

235 Summary data as published in this paper will be available, but other data are not publicly available
236 because of patient privacy restrictions decided by the Regional Ethical Committee. We may apply for
237 permission to share data with new collaborators, still adhering to patient privacy requirements of
238 the “Law of Health Research”. All code needed to replicate our described analyses is available upon
239 request from the corresponding author.

240 **RESULTS**

241 **Sample characteristics at baseline and follow-up**

242 Our MS sample included 71% (N=54) females, in line with the prevalence of MS in the general
243 population. At follow-up 44% (N=27) of the patients met criteria for NEDA-3. The median EDSS (2.0)
244 score did not change after five years. Only one patient developed secondary progressive MS (SPMS)
245 at follow-up. Mean time between baseline and follow-up was 4.5 years (SD = 0.4 years, range = 3.7-

246 5.4 years). Disease modifying treatment (DMT) were used by 78% and 69% of the patients at
 247 baseline and follow-up, respectively (table 1). The proportion of patients using second line
 248 treatment increased from 13% at baseline to 32% at follow-up. HCs were matched to the MS sample
 249 at baseline by age (HC mean years = 34.89, SD = 9.17) and sex (74% of HC were female). 70% of HCs
 250 from the Amsterdam sample were females, (mean age years = 41.86, SD = 11.44).

Table 1 Demographic and clinical characteristics of the multiple sclerosis patients

	Baseline	Follow-up
(a) Demographic characteristics	n=76	n= 62
Female, n (%)	54 (71)	44 (71)
Age, mean years (SD)	35.3 (7.3)	40.5 (7.2)
Disease duration, mean months (SD)	71.7 (63)	125.1 (60.2)
Age at first symptom, mean years (SD)	29.3 (6.7)	
Months since diagnosis, mean (SD)	14.0 (11.9)	66.4 (14.5)
<i>Disease modifying treatment</i>		
None, n (%)	17 (22)	19 (31)
First line treatment, n (%)	49 (65)	23 (37)
Second line treatment, n (%)	10 (13)	20 (32)
(b) Clinical evaluation		
<i>Multiple sclerosis classification</i>		
RRMS, n (%)	75 (99)	60 (96)
PPMS, n (%)	1 (1)	1 (2)
SPMS, n (%)		1 (2)
<i>Neurological disability</i>		
EDSS, median (SD, range)	2.0 (0.9, 0-6)	2.0 (1.3, 0-6)
MSSS (SD)	4.9 (1.9)	2.6 (1.8)
Number of total relapses, mean (SD)	1.8 (1)	2.6 (1.3)

FSS, mean (SD)	4.2 (1.7)	4.13 (1.9)
----------------	-----------	------------

(c) NEDA assessment

NEDA-3, n (%)	27 (44)
---------------	---------

OCB, oligoclonal bands; RRMS, relapsing-remitting multiple sclerosis; PPMS, primary-progressive multiple sclerosis; SPMS, secondary-progressive multiple sclerosis; EDSS, expanded disability status scale; MSSS, multiple sclerosis severity scale; FSS, fatigue severity scale; NEDA, no evidence of disease activity.

251

252 The performance of MS patients on all cognitive tests of the CWIT, in addition to the CVLT-II,
253 improved over time ([table e-3 in Supplemental Data](#)). The performance in symbol digit modalities
254 test, that also was used to investigate processing speed, did not change over time ([table e-3 in](#)
255 [Supplemental Data](#)). Both T25-FT and 9-hole peg test at follow-up did not show any significant
256 development when compared to baseline ([table e-3 in Supplemental Data](#)).

257 We found no effects of motion parameters such as signal to noise ratio and mean relative
258 motion with clinical and cognitive outcomes ([table e-4 in Supplemental Data](#)).

259 **Functional connectivity abnormalities in MS versus HCs at baseline**

260 Overall FC, for the complete combined functional connectome, was lower in MS patients compared
261 to HCs. FC within three of the four large-scale networks investigated was significantly decreased in
262 MS patients. After correction for multiple testing only network 1 and 2 remained significantly
263 different from controls ([table 2](#)). Edge wise analysis showed that a connection (IC11-IC15) in network
264 1 was weaker in MS relative to controls ($\beta = -0.1$, $t(135) = -5.21$, $p = .0002$), while another (IC6-IC11)
265 one was stronger in patients compared to HCs ($\beta = 0.07$, $t(135) = 3.54$, $p = .032$). An edge (IC10-IC14)
266 in network 2 was increased in MS ($\beta = 0.08$, $t(135) = 3.74$, $p = .002$) and within network 3 one
267 connection (IC7-IC16) decreased intensity in patients relative to controls ($\beta = -0.08$, $t(135) = -3.94$, p
268 $= .001$). Also, a connection (IC2-IC7) between networks 3 and 4 was altered in MS patients ($\beta = -$
269 0.08 , $t(135) = -4.02$, $p = .001$). [Figure 2](#) lists the comparisons in FC between MS and HCs at the level

270 of single connections, showing that FC abnormalities are bidirectional in MS ([figure e-1 in](#)
271 [Supplemental data for complete p values](#)).

272 FC did not change significantly over time in the MS cohort, as measured by paired sample t-
273 test between all ICs considered singularly, and between ICs grouped into networks, across time
274 ([figure e-2, e-3 and table e-5 in Supplemental Data](#)). Additional analysis including careful lesion
275 masking during the estimation of the node time series did not change the main effects or
276 interpretation of the results ([figure e-4 in Supplemental Data](#)).


277

Table 2 Within network functional connectivity abnormalities in MS

	Beta coefficient	T value	Standard deviation	P value
Full brain	-0.001	-1.28	0.001	0.2
Network 1	-0.017	-3.56	0.005	0.002 *
DMN and frontoparietal nodes				
Network 2	-0.011	-3.14	0.003	0.004 *
DMN and frontoparietal nodes				
Network 3	-0.009	-1.59	0.006	0.15
Auditory nodes				
Network 4	0.002	0.41	0.005	0.68
Sensory and motor nodes				

Results of multivariate linear regression models corrected for sex, age, mean relative motion and signal to noise ratio. P values corrected for multiple testing

by false discovery rate. * P value significant after correction for multiple testing by false discovery rate




278

279 **Figure 2** Edgewise analysis of functional connectivity abnormalities in MS vs HCs. T values form
280 multivariate linear regressions assessing differences in FC at the level of single connections between
281 MS and HCs. Warm colours indicate increased FC in MS, cold colours a decrease in FC. * P value
282 significant after correction for multiple testing by false discovery rate.

283

284 **Connectome stability over time**

285 The stability of the brain functional connectome in the whole MS cohort, and in the EDA and NEDA
286 subgroups are depicted in Figure 3, enabling visualization of FC reorganization. Connectome stability
287 of network 2 was lower in EDA patients compared to NEDA patients ($\beta = 0.14$, $t(34) = 2.26$, $p = .03$),
288 but did not survive correction for multiple testing (table e-6 in Supplemental Data).



289

290 **Figure 3** Stability of the brain functional connectome between baseline and follow-up for the MS
291 sample as a whole, and for the subgroups of EDA and NEDA, respectively for the global estimate and
292 all resulting networks. We found a trend where patients in the EDA subgroup compared to both
293 patients with NEDA and HC patients had improved connectome stability.


294

295 The analyses revealed a borderline significant association between connectome stability and change
296 in brain volume between baseline and follow-up, indicating that the larger changes in FC were
297 associated with increased brain volume loss over time, but no significant association was detected
298 with the accumulation of lesion volume over time (figure 4). We also checked for apparent relations
299 between motion parameters such as signal to noise ratio and mean relative motion and brain
300 atrophy and accumulation of lesion load, but we did not find any (table e-7 in Supplemental Data).

301

302 We correlated the stability of the brain functional connectome with the sum of the squared
303 differences in FC between baseline and FU, and we found that these two indices were highly related
($\rho = -0.59$, $p < .0001$).

304



305

306 **Figure 4** Correlation between structural damage and stability of the brain functional connectome.

307 (A) correlation between brain atrophy and the rate of FC reorganization, $\rho = 0.40$, $p = .06$. (B)

308 correlation between accumulation of lesion volume over time and the rate of FC reorganization, $\rho =$

309 0.13 , $p = .63$.

310

311 **Clinical relevance of functional connectivity changes**

312 Finally, we explored the effects of the changes in FC on cognitive performance and physical ability

313 using separate general linear models with average cognition and physical ability at FU as dependent


314 variables, covarying for age, sex, signal to noise ratio and mean relative motion. Younger age at FU

315 ($\beta = -0.03$, $t(34) = -2.08$, $p = .045$) was associated with better cognitive performance at FU (figure 5A).

316 Neither stability of the brain functional connectome, age, sex, signal to noise ratio nor mean relative

317 motion were associated with longitudinal changes in cognitive performance ($p > .05$) (figure 5B).

318 For physical ability, lower connectome stability ($\beta = 4.56$, $t(34) = 2.00$, $p = .05$), higher age at
319 FU ($\beta = -0.05$, $t(34) = -2.45$, $p = .02$) and sex, with women scoring better than men, ($\beta = 0.70$, $t(34) =$
320 2.46 , $p = .02$) were associated with decreased physical ability at FU (figure 5C). None of the
321 investigated variables were associated with changes in physical performance over time ($p > .05$)
322 (figure 5D).



323
324 **Figure 5** Effect of FC reorganization on cognitive performance and physical ability. (A) Effect of FC
325 reorganization on average cognition at follow-up, $\beta = 1.98$, $t(34) = 1.20$, $p = .27$. (B) Effect of FC
326 reorganization on average change in cognition, $\beta = 1.00$, $t(33) = 0.64$, $p = .52$. (C) Effect of FC
327 reorganization on physical ability at follow-up, $\beta = 4.56$, $t(34) = 2.00$, $p = .05$. (D) Effect of FC
328 reorganization on average change in physical ability, $\beta = 0.89$, $t(33) = 0.33$, $p = .75$.

329

330 **DISCUSSION**

331 In this study, we investigated clinical relevance of connectome stability as an individual-level global
332 marker of longitudinal FC changes, in a five years longitudinal prospective study of patients recently
333 diagnosed with MS. In addition, we performed a cross-sectional case-control comparison with a
334 matched group of healthy controls, assessing network- and edgewise FC differences between MS
335 patients and controls.

336 The case-control comparison replicated previous reports of bi-directional FC differences in
337 MS compared to a matched HC sample^{11, 40}, supporting our first hypothesis that FC aberrations are
338 present already in the early stages of MS.

339 Schoonheim et al. (2010) have proposed a model for functional reorganization of the brain
340 in relation to structural damage and clinical impairment in MS⁴¹, postulating that, at least in the early
341 stages of MS, functional connectivity would increase as a mechanism to suspend the effects of
342 microstructural damage occurring in the brain as a compensatory mechanism to delay clinical
343 disability. Since then, accumulating evidence has established that FC aberrations are in fact
344 bidirectional in MS¹¹, and the authors recognized the first model postulated was overly simplified¹³.
345 Although their intuition and conceptualization of the model for FC reorganization following disease
346 progression in MS was valid, we hypothesize that their measure for FC reorganization was
347 incomplete.

348 In this study, we present a novel approach enabling us to study individual longitudinal FC
349 reorganization in relation to disease progression in MS. Investigating the longitudinal stability of the
350 brain functional connectome allows us to study the complex dynamics of FC reorganization in MS,
351 finally enabling us to test the model presented by Schoonheim et al.⁴¹, considering not only the
352 increase in FC, but the whole complex interplay of FC changes following structural damage in MS.

353 In accordance with our hypothesis that disease progression in MS was associated with FC
354 reorganization as measured by connectome stability, we found that FC changed at a higher rate as
355 brain atrophy, but not lesion volume, increased. In line with the same hypothesis, we expected to

356 see increased FC reorganization in patients experiencing disease activity between baseline and
357 follow-up. Connectome stability in network (2) was lower in EDA patients compared to NEDA
358 patients, however the observed difference between these two sub-groups did not remain significant
359 after correcting for multiple testing.

360 Finally, we assessed the clinical relevance of the connectome stability measure in our
361 sample. We did not observe significant associations between connectome stability and progression
362 of cognitive and physical impairment. A possible reason might be that our MS cohort was
363 remarkably stable in the follow-up period, exemplified by observations that only two participants
364 displayed a significant decrease (defined as an annual reduction of > 0.25 SD in the five years follow-
365 up period) in physical ability, and none in average cognition ([figure e-5 and e-6 in Supplemental data](#)
366 [respectively](#)). Lower connectome stability was associated with lower physical ability at follow-up, but
367 the result was likely to be driven by two outliers performing very poorly at follow-up. We did not
368 detect any association between FC reorganization and average cognition at follow-up. According to
369 the model presented by Schoonheim et al⁴¹, FC reorganization delays the onset of clinical
370 impairment. Since we did not detect any worsening in the clinical performance of our MS patients
371 during the observed period of time, it is tempting to speculate whether the FC changes, that
372 occurred, delayed the onset of impairment. Therefore, it will be important to repeat these analyses
373 in a planned follow-up of the group of patients in a few years.

374 Using connectome stability as an individual-level longitudinal measure, by incorporating the
375 global dynamics of FC changes in the brain, has previously been used to study mental health in
376 adolescent neurodevelopment⁴² as well as severe mental disorders¹⁴, but has so far remained
377 unexplored in MS. The measure is based on longitudinal within-subjects Spearman correlation
378 coefficients^{14, 42}. Any change in FC that occurs over time, independent of the direction, will cause a
379 shift in ranks that lowers the Spearman correlation coefficient, thus providing a global measure
380 sensitive to relative FC reorganization. However, the shift in ranks of one connection causes the

381 following shift in ranks of all the others, potentially inflating the measure of connectome stability.
382 We correlated the index of connectome stability with the sum of the squared differences in FC to
383 control for possible artefacts due to the implementation of a rank-based measure. Since the
384 correlation is strong, highly significant and goes in the expected direction we are confident that
385 connectome stability is a valid approach to investigate FC reorganization in MS.

386 Our study is, to our knowledge, one of very few published studies investigating longitudinal
387 FC in MS^{40, 43}. In general, our results reproduced and confirmed the results reported by Rocca et al
388 and Koubiyr et al. (2019) investigating clinically isolated syndrome (CIS) patients in a longitudinal
389 setting^{40, 43}. All these studies show FC abnormalities at the early phases of the disease and, in line
390 with Rocca et al. we found that FC alterations do not correlate with lesion volume. Furthermore,
391 even though the main approach to study FC reorganization is different in these studies, all data-sets
392 suggest brain reorganization during disease progression.

393 A limitation of our study is that we could not investigate the difference in connectome
394 stability between HCs and MS patients due to the lack of MRI at follow-up for HCs. Since HCs
395 performed cognitive tests only at baseline, we used the results of HCs at baseline to create the Z-
396 scores for MS patients at follow-up. Z-scores for physical ability were based on analyses of
397 performance of MS patients only. Practice effects in cognitive tests seem to have occurred, but we
398 could not account for them, for example calculating the reliable change index as done by Eijlers et
399 al.²². The sample size of our MS cohort is comparable with that of previous studies investigating FC
400 longitudinally⁴⁰. In sub-group analyses the sample sizes are modest. Finally, functional connections
401 of the brain are known to be dynamic, and future studies with longer scan duration may be able to
402 pursue approaches for assessing the dynamic aspects of the FC in the brains of patients with MS.

403 To conclude, in this longitudinal study we found that our MS cohort was remarkably clinically
404 stable. Only two patients showed a significant decrease in physical ability and cognitive performance
405 was preserved in all participants in the follow-up period. We found that FC abnormalities are

406 bidirectional and occur already at the early stages of MS. We used the stability of the brain
407 functional connectome as a proxy for FC reorganization, enabling us to study FC changes in relation
408 to disease progression. We found that FC reorganization and brain atrophy advance in parallel. In
409 future studies, the MS cohort needs to be followed up again to enable further analyses of functional
410 brain changes and clinical course. Connectome stability enables fMRI data to be condensed into a
411 proxy as an individual marker of brain health in a personalized medical approach to complement the
412 existing biomarkers in MS⁴⁴.

413

414 **Acknowledgement**

415 We thank all patients participating in our studies. We acknowledge the collaboration with members
416 of the Multiple Sclerosis Research Group and NORMENT at the University of Oslo and Oslo University
417 hospital, especially Elisabeth G. Celius for her guidance during the investigations of the MS patients
418 and Tobias Kaufmann for valuable help and input on the statistical approach. We also thank the
419 research assistants Kristin Liltved Grønsberg, May-Britt Gjengstø Utheim, Julia Timofeeva, Hedda
420 Maurud, Siren Tønnessen and Petter Espeseth Emhjellen who all contributed in the cognitive testing
421 of the patients.

422

423 **Study funding**

424 The project was supported by grants from the South-Eastern Health Authorities of Norway (grant
425 number 2011059/ES563338/Biotek 2021) and by the European Union under the Horizon 2020
426 programme (grant number 733161).

427

428 **Disclosures**

429 E. A. Høgestøl has received honoraria for lecturing from Biogen, Merck and Sanofi-Genzyme, and
430 unrestricted research support from Merck and Sanofi-Genzyme. P. Sowa has received honoraria for
431 lecturing and travel support from Merck. M. K. Beyer has received honoraria for lecturing from
432 Novartis and Biogen Idec. H.F Harbo has received travel support, honoraria for advice or lecturing
433 from Biogen Idec, Sanofi-Genzyme, Merck, Novartis, Roche, and Teva and an unrestricted research
434 grant from Novartis. Hanneke Hulst received honoraria for speaking at scientific meetings, serving at
435 scientific advisory boards and consulting activities from Biogen, Celgene, Genzyme, Merck and
436 Roche. She has received research support from the Dutch MS Research foundation and serves on the
437 editorial board of Multiple Sclerosis Journal (MSJ). S. Ghezzi, G.O. Nygaard, T. Espeseth, L.T. Westlye
438 and D. Alnæs report no disclosures.

439 **Appendix**

440 Authors

Name	Location	Contribution
Einar A. Høgestøl, MD	Oslo University Hospital & University of Oslo	Conceived the study, data collection conception and design of the work, data analysis and interpretation, drafting the article, final approval of the version to be published
Samuele Ghezzi, BSc	Oslo University Hospital & University of Oslo	Data analysis and interpretation, drafting the article, final approval of the version to be published
Gro O. Nygaard, PhD	Oslo University Hospital	Conceived the study, data collection conception and design of the work, final approval of the version to be published
Thomas Espeseth, PhD	University of Oslo & Bjørknes College	Data collection, final approval of the version to be published
Piotr Sowa, MD, PhD	Oslo University Hospital	Data collection, final approval of the version to be published
Mona K. Beyer, PhD	Oslo University Hospital & University of Oslo	Data collection and design of the work, final approval of the version to be published
Hanne F. Harbo, PhD	Oslo University Hospital & University of Oslo	Conceived the study, data collection, conception and design of the work, final approval of the version to be published
Lars T. Westlye, PhD	Oslo University Hospital & University of Oslo	Data analysis and interpretation, final approval of the version to be published

		published
Hanneke E. Hulst, PhD	Amsterdam UMC & Vrije Universiteit Amsterdam	Data analysis and interpretation, drafting the article, final approval of the version to be published
Dag Alnæs, PhD	Oslo University Hospital & University of Oslo	Data analysis and interpretation, drafting the article, final approval of the version to be published

441

442 REFERENCES

- 443 1. Barkhof F. The clinico-radiological paradox in multiple sclerosis revisited. *Current opinion in*
444 *neurology* 2002;15:239-245.
- 445 2. Chard D, Trip SA. Resolving the clinico-radiological paradox in multiple sclerosis. *F1000Res*
446 2017;6:1828.
- 447 3. Peer M, Nitzan M, Bick AS, Levin N, Arzy S. Evidence for Functional Networks within the
448 Human Brain's White Matter. *J Neurosci* 2017;37:6394-6407.
- 449 4. Smith SM, Fox PT, Miller KL, et al. Correspondence of the brain's functional architecture
450 during activation and rest. *Proceedings of the National Academy of Sciences of the United States of*
451 *America* 2009;106:13040-13045.
- 452 5. Basile B, Castelli M, Monteleone F, et al. Functional connectivity changes within specific
453 networks parallel the clinical evolution of multiple sclerosis. *Multiple sclerosis (Houndmills,*
454 *Basingstoke, England)* 2014;20:1050-1057.
- 455 6. Rocca MA, Valsasina P, Martinelli V, et al. Large-scale neuronal network dysfunction in
456 relapsing-remitting multiple sclerosis. *Neurology* 2012;79:1449-1457.
- 457 7. d'Ambrosio A, Valsasina P, Gallo A, et al. Reduced dynamics of functional connectivity and
458 cognitive impairment in multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)*
459 2019:1352458519837707.
- 460 8. Rocca MA, Valsasina P, Leavitt VM, et al. Functional network connectivity abnormalities in
461 multiple sclerosis: Correlations with disability and cognitive impairment. *Multiple sclerosis*
462 *(Houndmills, Basingstoke, England)* 2018;24:459-471.
- 463 9. Havelle DJ, Hipp JF, Lewis CM, Corbetta M, Engel AK. Increased functional connectivity
464 indicates the severity of cognitive impairment in multiple sclerosis. *Proceedings of the National*
465 *Academy of Sciences of the United States of America* 2011;108:19066-19071.
- 466 10. Rocca MA, Valsasina P, Absinta M, et al. Default-mode network dysfunction and cognitive
467 impairment in progressive MS. *Neurology* 2010;74:1252-1259.
- 468 11. Tahedl M, Levine SM, Greenlee MW, Weissert R, Schwarzbach JV. Functional Connectivity in
469 Multiple Sclerosis: Recent Findings and Future Directions. *Frontiers in neurology* 2018;9:828.
- 470 12. Faivre A, Rico A, Zaaraoui W, et al. Assessing brain connectivity at rest is clinically relevant in
471 early multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke, England)* 2012;18:1251-1258.
- 472 13. Schoonheim MM, Meijer KA, Geurts JJ. Network collapse and cognitive impairment in
473 multiple sclerosis. *Frontiers in neurology* 2015;6:82.
- 474 14. Kaufmann T, Alnaes D, Brandt CL, et al. Stability of the Brain Functional Connectome
475 Fingerprint in Individuals With Schizophrenia. *JAMA psychiatry* 2018;75:749-751.
- 476 15. Nygaard GO, Walhovd KB, Sowa P, et al. Cortical thickness and surface area relate to specific
477 symptoms in early relapsing-remitting multiple sclerosis. *Multiple sclerosis (Houndmills, Basingstoke,*
478 *England)* 2015;21:402-414.
- 479 16. Nygaard GO, Celius EG, de Rodez Benavent SA, et al. A Longitudinal Study of Disability,
480 Cognition and Gray Matter Atrophy in Early Multiple Sclerosis Patients According to Evidence of
481 Disease Activity. *PloS one* 2015;10:e0135974.

- 482 17. Høgestøl EA, Kaufmann T, Nygaard GO, et al. Cross-Sectional and Longitudinal MRI Brain
483 Scans Reveal Accelerated Brain Aging in Multiple Sclerosis. *Frontiers in neurology* 2019;10.
- 484 18. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010
485 revisions to the McDonald criteria. *Annals of neurology* 2011;69:292-302.
- 486 19. Espeseth T, Christoforou A, Lundervold AJ, Steen VM, Le Hellard S, Reinvang I. Imaging and
487 cognitive genetics: the Norwegian Cognitive NeuroGenetics sample. *Twin Res Hum Genet*
488 2012;15:442-452.
- 489 20. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to
490 patients with multiple sclerosis and systemic lupus erythematosus. *Archives of neurology*
491 1989;46:1121-1123.
- 492 21. Penner IK, Paul F. Fatigue as a symptom or comorbidity of neurological diseases. *Nature*
493 *reviews Neurology* 2017.
- 494 22. Eijlers AJC, van Geest Q, Dekker I, et al. Predicting cognitive decline in multiple sclerosis: a 5-
495 year follow-up study. *Brain : a journal of neurology* 2018;141:2605-2618.
- 496 23. Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface
497 reconstruction. *NeuroImage* 1999;9:179-194.
- 498 24. Reuter M, Schmansky NJ, Rosas HD, Fischl B. Within-subject template estimation for
499 unbiased longitudinal image analysis. *NeuroImage* 2012;61:1402-1418.
- 500 25. Brewer JB. Fully-automated volumetric MRI with normative ranges: translation to clinical
501 practice. *Behav Neurol* 2009;21:21-28.
- 502 26. W. Luo KL, A. M. Ulug, J. Albright, S. Magda, R. Haxton, C. Airriess. *LesionQuant Performance*
503 *Evaluation Accuracy and Reproducibility (white paper): Cortechs Labs, 2017.*
- 504 27. Damangir S, Manzouri A, Oppedal K, et al. Multispectral MRI segmentation of age related
505 white matter changes using a cascade of support vector machines. *Journal of the neurological*
506 *sciences* 2012;322:211-216.
- 508 28. Smith SM, Jenkinson M, Woolrich MW, et al. Advances in functional and structural MR image
509 analysis and implementation as FSL. *NeuroImage* 2004;23 Suppl 1:S208-219.
- 510 29. Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the robust and
511 accurate linear registration and motion correction of brain images. *NeuroImage* 2002;17:825-841.
- 512 30. Smith SM. Fast robust automated brain extraction. *Human brain mapping* 2002;17:143-155.
- 513 31. Smith SM, Brady JM. SUSAN—A New Approach to Low Level Image Processing. *International*
514 *Journal of Computer Vision* 1997;23:45-78.
- 515 32. Beckmann CF, DeLuca M, Devlin JT, Smith SM. Investigations into resting-state connectivity
516 using independent component analysis. *Philosophical transactions of the Royal Society of London*
517 *Series B, Biological sciences* 2005;360:1001-1013.
- 518 33. Griffanti L, Salimi-Khorshidi G, Beckmann CF, et al. ICA-based artefact removal and
519 accelerated fMRI acquisition for improved resting state network imaging. *NeuroImage* 2014;95:232-
520 247.
- 521 34. Pruim RH, Mennes M, van Rooij D, Llera A, Buitelaar JK, Beckmann CF. ICA-AROMA: A robust
522 ICA-based strategy for removing motion artifacts from fMRI data. *NeuroImage* 2015;112:267-277.
- 523 35. Nickerson LD, Smith SM, Ongur D, Beckmann CF. Using Dual Regression to Investigate
524 Network Shape and Amplitude in Functional Connectivity Analyses. *Front Neurosci* 2017;11:115.
- 525 36. Ledoit O, Wolf M. Improved estimation of the covariance matrix of stock returns with an
526 application to portfolio selection. *Journal of Empirical Finance* 2003;10:603-621.
- 527 37. Brier MR, Mitra A, McCarthy JE, Ances BM, Snyder AZ. Partial covariance based functional
528 connectivity computation using Ledoit-Wolf covariance regularization. *NeuroImage* 2015;121:29-38.
- 529 38. R: A Language and Environment for Statistical Computing [computer program]. Vienna,
530 Austria: R Foundation for Statistical Computing, 2017.
- 531 39. Singh KD, Barnes GR, Hillebrand A. Group imaging of task-related changes in cortical
532 synchronisation using nonparametric permutation testing. *NeuroImage* 2003;19:1589-1601.

- 533 40. Rocca MA, Hidalgo de La Cruz M, Valsasina P, et al. Two-year dynamic functional network
534 connectivity in clinically isolated syndrome. Multiple sclerosis (Houndmills, Basingstoke, England)
535 2019;1352458519837704.
- 536 41. Schoonheim MM, Geurts JJ, Barkhof F. The limits of functional reorganization in multiple
537 sclerosis. Neurology 2010;74:1246-1247.
- 538 42. Kaufmann T, Alnaes D, Doan NT, Brandt CL, Andreassen OA, Westlye LT. Delayed
539 stabilization and individualization in connectome development are related to psychiatric disorders.
540 Nature neuroscience 2017.
- 541 43. Koubiyr I, Besson P, Deloire M, et al. Dynamic modular-level alterations of structural-
542 functional coupling in clinically isolated syndrome. Brain : a journal of neurology 2019;142:3428-
543 3439.
- 544 44. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple
545 sclerosis. Multiple sclerosis and related disorders 2016;9 Suppl 1:S5-S48.
- 546